Keystone Programs for Collaborative Discovery Launch at... ( PHILADELPHIA (Feb. 27 2008) Fox Cha...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Keystone Programs for Collaborative Discovery Launch at Fox Chase

Date:2/27/2008

PHILADELPHIA (Feb. 27, 2008) Fox Chase Cancer Center today announced the first four awards in an innovative new research program designed to bring the power of team-based science to bear on some of the most significant questions in cancer research. The Keystone Programs for Collaborative Discovery aim to accelerate the pace of medical progress against cancer.

At the heart of each of the four new Keystone Programs is a self-organized group of scientists, clinicians, and other research professionals seeking to integrate and focus their joined expertise on an important cancer problem. Selected after a competitive external peer-review process, each of the new Keystone Programs will receive at least $5 million in support over five years. The funding will come primarily from new sources, including Fox Chases Board of Directors and private philanthropy. Additional Keystone Programs are in development and will be added to the portfolio as soon as is feasible.

The Keystone Programs for Collaborative Discovery represent an unprecedented reimagining of Fox Chases research enterprise to seize the opportunities for progress against cancer unique to this moment in scientific history, says Michael V. Seiden, M.D., Ph.D., president and CEO of Fox Chase Cancer Center. In the post-genomic era, the next wave of major advances against disease will depend on self-assembled teams of researchers from different fields effectively pooling their skills and resources. The Keystone Programs were designed specifically to encourage and support the kind of creative team-based science at Fox Chase that will be required to solve the most challenging cancer problems.

The first four Keystone Programs for Collaborative Discovery are:

The Keystone Program in Personalized Risk and Prevention
Goal: To discover molecular markers that predict cancer risk and to develop risk reduction strategies tailored to the profile and personal values of the individual

'/>"/>

Contact: Franklin Hoke
franklin.hoke@fccc.edu
215-728-2700
Fox Chase Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Keystone Human Services Acquires Impact Systems, Inc.
2. Temple University Hospital, Temple University School of Medicine and Crozer-Keystone Health System Collaborate to Provide Comprehensive Kidney Care
3. MB Software Corporation Reaches Agreement with Keystone Equity Partners
4. AthletixNation.com Launches Sports Website and Community Programs
5. New Legal Momentum Publication Exposes How Abstinence-Only Programs Harm Women and Girls
6. New Government Data: Mail-Service Pharmacies Grow, But Public Programs Lag Behind
7. Portable Computer Devices Can Aid Exercise Programs
8. High-End Treatment Center Moonview Sanctuary Unveils Four New Core Treatment Programs
9. Bush Budget Cuts Federal Health Programs Vital to the Health of All Children
10. Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs
11. Training Magazine Applauds Aflacs Employee Learning Programs

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer 2 Health News:Macomb County Announces New Location for Four Upcoming H1N1 Clinics 2 Health News:American Association of Poison Control Centers: Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season 2 Health News:State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans 2 Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 2 Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 3

[0] Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer [0] Macomb County Announces New Location for Four Upcoming H1N1 Clinics [0] American Association of Poison Control Centers: Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season [0] State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans [0] Mechanism discovered by which body's cells encourage tuberculosis infection

Growth hormone is used to treat twice as many short boys than girls in the US and Asia Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities U-M study: Work hassles hamper sleep Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data

Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2 Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10 China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2 China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3 AMD LASERS Announces Partnerships With Three Industry Leading Companies 5686 1 Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 1 Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 2 Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 3 Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 1 Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 2

[0] Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign [0] Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection [0] China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010

Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2 New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3 New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4 New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia

Medicine Products:

iRISystem AgileTrac™ Instrument Manager WatchMate MR RoamAlert Integrity Plus

Keystone Programs for Collaborative Discovery Launch at...( PHILADELPHIA (Feb. 27 2008) Fox Cha...),Health